AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36418274 — intervention group
Group type: COMPARATOR
Intervention: CPD plus RA
Number of subjects: 60
Study 36226385 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention (verbal explanation and demonstration of inhaler technique with metered-dose inhaler using a mannequin)
Number of subjects: 84
Study 35675658 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-Week Self-administered Home-Based Virtual Reality Program
Number of subjects: 0
Study 32443695 — intervention group
Group type: EXPERIMENTAL
Intervention: Aronia melanocarpa juice (AMJ) treatment, 1.17 g/100 mL polyphenols
Number of subjects: 19
Study 32443695 — intervention group
Group type: EXPERIMENTAL
Intervention: low‐polyphenol Aronia melanocarpa juice (dAMJ) treatment, 0.29 g/100 mL polyphenols
Number of subjects: 19
Study 32443695 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 19
Study 35034867 — intervention group
Group type: EXPERIMENTAL
Intervention: LUTS self-management booklet delivered by health care staff
Number of subjects: 1077
Study 35034867 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1077
Study 33736920 — intervention group
Group type: EXPERIMENTAL
Intervention: GC3110A (quadrivalent inactivated split-virion influenza vaccine)
Number of subjects: 200
Study 33736920 — intervention group
Group type: COMPARATOR
Intervention: Control TIV (inactivated trivalent influenza vaccine)
Number of subjects: 200
Study 33375942 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Vivomixx®
Number of subjects: 110
Study 33375942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 34963031 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic training (3 times a week, including 5 min warm-up, 50 min aerobic dancing, and 5 min relaxation)
Number of subjects: 106
Study 34963031 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 106
Study 32033935 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) monotherapy
Number of subjects: 4
Study 32033935 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) monotherapy
Number of subjects: 4
Study 32033935 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) monotherapy
Number of subjects: 4
Study 33249268 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2%
Number of subjects: 80
Study 33249268 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 80
Study 32868680 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) 2 times per week (G2x)
Number of subjects: 40
Study 32868680 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) 3 times per week (G3x)
Number of subjects: 40
Study 32868680 — intervention group
Group type: COMPARATOR
Intervention: Detraining period
Number of subjects: 40
Study 32868680 — intervention group
Group type: EXPERIMENTAL
Intervention: Retraining period
Number of subjects: 40
Study 32130742 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment 1
Number of subjects: 0
Study 32130742 — intervention group
Group type: COMPARATOR
Intervention: Treatment 0
Number of subjects: 0
Study 33052796 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose octasulfate dressing
Number of subjects: 0
Study 33052796 — intervention group
Group type: COMPARATOR
Intervention: Control dressing (neutral dressing)
Number of subjects: 0
Study 35466057 — intervention group
Group type: EXPERIMENTAL
Intervention: Spherical silicone hydrogel
Number of subjects: 10
Study 35466057 — intervention group
Group type: COMPARATOR
Intervention: Non-lens wear
Number of subjects: 10
Study 34784577 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg plus androgen deprivation therapy (ADT)
Number of subjects: 1401
Study 34784577 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus androgen deprivation therapy (ADT)
Number of subjects: 1401
Study 34759176 — intervention group
Group type: EXPERIMENTAL
Intervention: Difluprednate 0.05% nanoemulsion (DIFL) twice a day
Number of subjects: 259
Study 34759176 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone acetate 1% + phenylephrine hydrochloride 0.12% suspension (PRED) 4 times a day
Number of subjects: 259
Study 33625363 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored mobile coaching (TMC) system
Number of subjects: 72
Study 35488332 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis using partial least square-discriminate analysis (PLS-DA) with Mean Center preprocess method.
Number of subjects: 30
Study 35488332 — intervention group
Group type: COMPARATOR
Intervention: Univariate analysis.
Number of subjects: 30
Study 34167458 — intervention group
Group type: EXPERIMENTAL
Intervention: SM at T4
Number of subjects: 82
Study 34167458 — intervention group
Group type: COMPARATOR
Intervention: SM at T8
Number of subjects: 82
Study 34167458 — intervention group
Group type: COMPARATOR
Intervention: Placebo (light mechanical stimulus at T4)
Number of subjects: 82
Study 35559733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 72
Study 35559733 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 72
Study 33258534 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral α-lipoic acid (ALA) 300 mg daily for 6 months + NB-UVB phototherapy
Number of subjects: 133
Study 33258534 — intervention group
Group type: COMPARATOR
Intervention: Placebo + NB-UVB phototherapy
Number of subjects: 133
Study 34370970 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 1437
Study 34370970 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 1437
Study 34370970 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 1437
Study 34370970 — intervention group
Group type: COMPARATOR
Intervention: Insulin degludec
Number of subjects: 1437
Study 32047578 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischaemic Preconditioning (RIPC)
Number of subjects: 56
Study 32047578 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 56
Study 35800230 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior lateral malleolus plate fixation
Number of subjects: 80
Study 35800230 — intervention group
Group type: COMPARATOR
Intervention: Lateral malleolus plate fixation
Number of subjects: 80
Study 33122081 — intervention group
Group type: EXPERIMENTAL
Intervention: Liability to Major Depressive Disorder (MDD)
Number of subjects: 0
Study 33122081 — intervention group
Group type: EXPERIMENTAL
Intervention: Liability to insomnia
Number of subjects: 0
Study 36027238 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated drink (3 mg/kg)
Number of subjects: 19
Study 36027238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 33848764 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage and autogenous bone grafting (Group 1)
Number of subjects: 200
Study 33848764 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage and bone graft substitutes (Group 2)
Number of subjects: 200
Study 33848764 — intervention group
Group type: COMPARATOR
Intervention: Curettage only (Group 3)
Number of subjects: 200
Study 36418946 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ug/kg intranasal DEX plus 0.2 mg/Kg oral midazolam
Number of subjects: 156
Study 36418946 — intervention group
Group type: COMPARATOR
Intervention: 2 ug/kg intranasal DEX plus 0.2 mg/Kg oral Midazolam
Number of subjects: 156
Study 33420214 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous and intraperitoneal analgesia
Number of subjects: 119
Study 33420214 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous analgesia and intraperitoneal placebo
Number of subjects: 119
Study 33420214 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous placebo and intraperitoneal analgesia
Number of subjects: 119
Study 33420214 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous and intraperitoneal placebo
Number of subjects: 119
Study 33580351 — intervention group
Group type: EXPERIMENTAL
Intervention: Expander with differential opening (EDO)
Number of subjects: 48
Study 33580351 — intervention group
Group type: COMPARATOR
Intervention: Fan-type expander (FE)
Number of subjects: 48
Study 33580351 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EDO and FE
Number of subjects: 48
Study 35396310 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion from 20:00 to 08:00 post-surgery
Number of subjects: 348
Study 35396310 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 348
Study 35396310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study 33682262 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (REG)
Number of subjects: 107
Study 33327266 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis with alteplase combined with edaravone
Number of subjects: 118
Study 33327266 — intervention group
Group type: COMPARATOR
Intervention: Intravenous thrombolysis of alteplase
Number of subjects: 118
Study 35472628 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous IV epinephrine infusion (0.00375 mg/kg/min) with placebo IV normal saline (NS) boluses every 4 min
Number of subjects: 45
Study 35472628 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous placebo IV NS infusion with IV epinephrine boluses (0.015 mg/kg) every 4 min
Number of subjects: 45
Study 35472628 — intervention group
Group type: COMPARATOR
Intervention: Placebo IV NS for both infusion and boluses
Number of subjects: 45
Study 34479759 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norms nudges
Number of subjects: 6230
Study 34479759 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminding the impact on beneficiaries
Number of subjects: 6230
Study 34479759 — intervention group
Group type: EXPERIMENTAL
Intervention: Defaults nudges (high vaccination intention)
Number of subjects: 6230
Study 35575611 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg/d)
Number of subjects: 14641
Study 35575611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14641
Study 35575611 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU every other day)
Number of subjects: 14641
Study 34698461 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingnan fire needling combined with 0.1% sodium hyaluronate eye drops
Number of subjects: 86
Study 34698461 — intervention group
Group type: COMPARATOR
Intervention: 0.1% sodium hyaluronate eye drops
Number of subjects: 86
Study 32329069 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigenetic signature (11 epigenetic factors)
Number of subjects: 0
Study 32329069 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram integrating epigenetic signature, pathological stage, and postoperative chemotherapy
Number of subjects: 0
Study 32329069 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive signature
Number of subjects: 0
Study 32329069 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation series (combination of GSE17538, GSE33113, GSE37892)
Number of subjects: 0
Study 35784723 — intervention group
Group type: EXPERIMENTAL
Intervention: Molnupiravir (800 mg) plus basic treatment for 5 days (BID)
Number of subjects: 0
Study 35784723 — intervention group
Group type: COMPARATOR
Intervention: Control group (only basic treatment)
Number of subjects: 0
Study 35784723 — intervention group
Group type: EXPERIMENTAL
Intervention: Molnupiravir (800 mg)
Number of subjects: 0
Study 32493478 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 400 mg orally daily for 3 days then 200 mg orally daily for an additional 11 days (total 14 days)
Number of subjects: 2000
Study 32493478 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid 500 mg orally daily for 3 days then 250 mg orally daily for 11 days (total 14 days)
Number of subjects: 2000
Study 32493478 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 2000
Study 36032243 — intervention group
Group type: EXPERIMENTAL
Intervention: TRI 360TM capsules twice a day
Number of subjects: 84
Study 36032243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 32134163 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 mg/kg
Number of subjects: 44
Study 32134163 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg
Number of subjects: 44
Study 32134163 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Number of subjects: 44
Study 36321411 — intervention group
Group type: EXPERIMENTAL
Intervention: Active titration
Number of subjects: 172
Study 36321411 — intervention group
Group type: COMPARATOR
Intervention: Usual titration
Number of subjects: 172
Study 35918281 — intervention group
Group type: EXPERIMENTAL
Intervention: Videographic and plaque disclosing tablets (PDT)
Number of subjects: 96
Study 35918281 — intervention group
Group type: COMPARATOR
Intervention: Verbal instructions
Number of subjects: 96
Study 35918281 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque disclosing tablets (PDT)
Number of subjects: 96
Study 35918281 — intervention group
Group type: EXPERIMENTAL
Intervention: Video group
Number of subjects: 96
Study 35082248 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation (MM)
Number of subjects: 328
Study 35082248 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis (HYP)
Number of subjects: 328
Study 35082248 — intervention group
Group type: COMPARATOR
Intervention: Education (ED)
Number of subjects: 328
Study 34653498 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy breakfast drinks varying in protein content and quantity
Number of subjects: 25
Study 33044886 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training program (twice/week over three months plus traditional physical rehabilitation)
Number of subjects: 34
Study 33044886 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical rehabilitation program (45 minutes/session, twice/week for three months)
Number of subjects: 34
Study 35068726 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention for tobacco cessation
Number of subjects: 200
Study 33374471 — intervention group
Group type: EXPERIMENTAL
Intervention: GRSAPN (5 SNPs significantly associated with APN level)
Number of subjects: 0
Study 33374471 — intervention group
Group type: EXPERIMENTAL
Intervention: GRSAll (47 SNPs from GWAS)
Number of subjects: 0
Study 33374471 — intervention group
Group type: EXPERIMENTAL
Intervention: GRSLimited (16 GRSAll-SNPs with p < 5.0 × 10−8)
Number of subjects: 0
Study 35551149 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir + Rilpivirine (early-switch group)
Number of subjects: 513
Study 35551149 — intervention group
Group type: COMPARATOR
Intervention: CAR (control group)
Number of subjects: 513
Study 33949942 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive peripheral nerve stimulation (NPNS)
Number of subjects: 37
Study 33949942 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 37
Study 34072874 — intervention group
Group type: EXPERIMENTAL
Intervention: SNL-based RF model
Number of subjects: 155
Study 34072874 — intervention group
Group type: EXPERIMENTAL
Intervention: WA-based RF model
Number of subjects: 155
Study 34072874 — intervention group
Group type: EXPERIMENTAL
Intervention: FR-based RF model
Number of subjects: 155
Study 34072874 — intervention group
Group type: COMPARATOR
Intervention: SVM models
Number of subjects: 155
Study 33820778 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR T-cell therapy
Number of subjects: 71
Study 36154278 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (6 cycles) and evofosfamide (11 cycles)
Number of subjects: 1
Study 36154278 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin (24 cycles)
Number of subjects: 1
Study 36154278 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (14 months)
Number of subjects: 1
Study 36154278 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine monotherapy (5 months)
Number of subjects: 1
Study 34189869 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab + Bevacizumab (ATEZO/BEV)
Number of subjects: 0
Study 34189869 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib (SOR)
Number of subjects: 0
Study 32017005 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3®
Number of subjects: 120
Study 32017005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 32017005 — intervention group
Group type: COMPARATOR
Intervention: VSL#3® vs Placebo
Number of subjects: 120
Study 35322144 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g/day of gluten for 2 weeks; gluten-tolerating subjects received 16 g/day for 2 weeks and then 32 g/day for a further 2 weeks
Number of subjects: 50
Study 35322144 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FODMAP strict gluten-free diet (GFD)
Number of subjects: 50
Study 35322144 — intervention group
Group type: COMPARATOR
Intervention: Gluten-containing diet
Number of subjects: 50
Study 33876241 — intervention group
Group type: EXPERIMENTAL
Intervention: X-ray-guided interventional procedures (EVAR procedures)
Number of subjects: 70
Study 32967939 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus radiotherapy
Number of subjects: 67
Study 32967939 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 67
Study 36102414 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Hz frequency
Number of subjects: 19
Study 36102414 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 Hz frequency
Number of subjects: 19
Study 36102414 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 KHz frequency
Number of subjects: 19
Study 36102414 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal waveform
Number of subjects: 19
Study 36102414 — intervention group
Group type: EXPERIMENTAL
Intervention: Square waveform
Number of subjects: 19
Study 36102414 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 μs‐pulsed waveform
Number of subjects: 19
Study 36102414 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional electrode configuration
Number of subjects: 19
Study 36102414 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric electrode configuration
Number of subjects: 19
Study 34992749 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (ImRs)
Number of subjects: 90
Study 34992749 — intervention group
Group type: COMPARATOR
Intervention: Usual Care and Treatment Advice (UC+TA)
Number of subjects: 90
Study 35807911 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy cooking training only
Number of subjects: 340
Study 35807911 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsidization with healthy cooking training
Number of subjects: 340
Study 35807911 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 340
Study 32803439 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative submucosal corticosteroid injection (n = 16), 8 mg/2 ml dexamethasone 21‐phosphate
Number of subjects: 52
Study 32803439 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative therapeutic elastic bandage application (n = 19), Kinesio tapes applied to operated sites
Number of subjects: 52
Study 32803439 — intervention group
Group type: COMPARATOR
Intervention: Postoperative non‐steroid anti‐inflammatory drug therapy (n = 17), 25 mg dexketoprofen trometamol
Number of subjects: 52
Study 34718947 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted GenerationPMTO (CAPAS-Youth)
Number of subjects: 71
Study 34718947 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 71
Study 34872117 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 54
Study 34872117 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Aerobic Training (CAT)
Number of subjects: 54
Study 34872117 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 54
Study 32528568 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg once daily (30 mg for creatinine clearance 15-50 mL/min, weight ≤ 60 kg, and/or concomitant use of P-glycoprotein inhibitor)
Number of subjects: 2199
Study 32528568 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin-warfarin
Number of subjects: 2199
Study 32528568 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 2199
Study 35694711 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal moxibustion on the navel combined with mind-regulating acupuncture
Number of subjects: 60
Study 35694711 — intervention group
Group type: COMPARATOR
Intervention: Herbal moxibustion on the navel
Number of subjects: 60
Study 36041346 — intervention group
Group type: EXPERIMENTAL
Intervention: Securement Bundle 2 (two sterile tape strips over PIVC hub plus Standard care)
Number of subjects: 109
Study 36041346 — intervention group
Group type: EXPERIMENTAL
Intervention: Securement Bundle 1 (two sterile tape strips over PIVC hub plus Standard care)
Number of subjects: 109
Study 36041346 — intervention group
Group type: COMPARATOR
Intervention: Standard care (bordered polyurethane dressing plus non-sterile tape over extension tubing)
Number of subjects: 109
Study 36041346 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence rate ratio for PIVC failure/1000 catheter days for Bundle 1 compared to Standard care
Number of subjects: 109
Study 36041346 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence rate ratio for PIVC failure/1000 catheter days for Bundle 2 compared to Standard care
Number of subjects: 109
Study 33586583 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuma longa L. (500 mg/day with piperine 5 mg)
Number of subjects: 71
Study 33196676 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact-guided replica-exchange molecular dynamics (REMD) with approximately 75% true-positive contacts
Number of subjects: 0
Study 33196676 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of varying numbers of randomly selected native and non-native contacts
Number of subjects: 0
Study 33196676 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact-guided REMD
Number of subjects: 0
Study 35184724 — intervention group
Group type: EXPERIMENTAL
Intervention: No sentinel lymph node biopsy (no-SLNB)
Number of subjects: 1734
Study 35184724 — intervention group
Group type: COMPARATOR
Intervention: Sentinel lymph node biopsy (SLNB)
Number of subjects: 1734